EVT (ASX:EVT) Clears Its Biggest Debt Risk With $750M Refinancing: Should You Buy the Hotel Growth Story?
EVT clears debt risk as hotel growth builds
EVT Limited (ASX: EVT) started the week with a piece of genuinely good news. The company increased its main debt facility from A$650 million to A$750 million at lower interest rates, clearing a debt maturity that was looming in May 2026 while securing an extra A$100 million in firepower for future hotel growth. For investors who have been watching this stock, that overhang is now gone. But with the hotel business firing and the cinema division struggling, the real question this Thursday morning is whether EVT is worth buying at current levels.
What are the Best ASX Stocks to invest in right now?
Check our buy/sell tips
EVT’s Hotel Machine Is the Real Story
The hotel business is where EVT’s growth story lives, and the numbers have been hard to ignore. The company runs 99 hotels with nearly 16,000 rooms across Australia and New Zealand, making it the second-largest hotel operator in the region. Reported net profit after tax rose 21.6% to A$37.8 million, and the company recently paid a fully franked interim dividend of A$0.18 per share, which tells you management is confident about where the business is heading.
What makes this more interesting is how EVT is growing. The QT Hotels brand continues to expand, while the Connect Hospitality platform allows the company to manage properties it does not own, earning fees without tying up large amounts of capital. That is a smarter, lighter way to scale.
We believe the refinancing accelerates this story. Cheaper debt means lower interest costs flowing directly into margins, which should strengthen free cash flow over the next few years. When lenders agree to refinance at better terms, it is also a vote of confidence in the underlying business. In this case, the banks are clearly backing the hotel transformation.
The Cinema Problem Isn’t Going Away
This is where the story gets harder. EVT’s Australian entertainment EBITDA fell 22.4%, and the New Zealand cinema business is now running at a loss. Management has pointed to a soft Hollywood release schedule as one reason, and that is fair enough. A weak lineup does hurt ticket sales.
To be balanced, January 2026 showed a sharp, blockbuster-led recovery with entertainment group EBITDA surging 355% to A$11.1 million, driven by Avatar: Fire and Ash and Zootopia 2. That is an encouraging sign. But investors should think carefully before treating the broader picture as a temporary blip. Streaming has permanently changed how people spend their evenings, and one strong month does not reverse that underlying shift. The cinema business still consumes capital and management focus, which remains a drag on an otherwise improving company.
The Investor’s Takeaway for EVT
The refinancing removes the most immediate risk hanging over this stock, and that matters. Cheaper debt, a stronger balance sheet, an extra A$100 million in available liquidity, and a growing hotel portfolio give EVT a solid foundation heading into the second half of the year.
For growth-oriented investors, the hotel compounding story is real, and the earnings momentum backs it up. At current levels, the stock looks reasonably priced if hotels keep delivering.
For more conservative investors, we would want to see the cinema division sustain its January momentum across a full half-year before getting too comfortable. One strong month is encouraging, but a consistent trend would go much further towards building confidence in the full picture.
EVT cleared its biggest near-term risk this week. Whether the hotel growth story can outrun the structural cinema decline is the question worth watching from here.
Blog Categories
Get the Latest Insider Trades on ASX!
Recent Posts
Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint
Rebound gains fuel as FDA orphan tag backs 38-patient efti data Immutep (ASX:IMM) has received FDA orphan drug designation for…
Telix Pharmaceuticals (ASX:TLX) refinances with US$600m 2031 convert at 1.5% coupon
Raises US$600m convert, cuts refinancing risk ahead of Pixclara PDUFA Telix Pharmaceuticals (ASX:TLX) is sourcing US$600 million of convertible debt,…
Stars And Stripes Income: The 6 Best American stocks for Australian investors in 2026!
Stocks Down Under recaps tha Best American stocks for Australian investors! We know that many Australian investors look beyond the…